Topic Intelligence
Articles and insights tagged Cannabidiol (CBD) on FAQSIR.
1933 Industries achieved record financial results for Fiscal 2024, reporting revenues of $19.3 million and a reduced net loss, showcasing operational efficiency and brand strength.
Following the U.S. Department of Justice's reclassification of certain marijuana products, WEED Inc. (OTCQB:BUDZ) discusses the implications for its legacy genetics portfolio.
Charlie's Holdings has announced the discontinuation of its hemp and CBD product sales, alongside the closure of its Don Polly division, as part of a strategic move to enhance stock liquidity and prepare for an uplisting.
WEED Inc. is evaluating strategic options involving its Sugar Hill asset and corporate initiatives to maximize shareholder returns, signaling potential developmental opportunities.
1933 Industries is set to finalize its acquisition of a 9% interest in its subsidiary, Alternative Medicine Association, enhancing its control in the cannabis market.
The enhanced partnership between Ovation Science and Skinvisible Pharmaceuticals aims to leverage innovative cannabinoid delivery technology for obesity treatments, addressing significant market needs and offering promising therapeutic options.
LFTD Partners plans to expand into the Illinois cannabis market by acquiring licenses and facilities. This move reflects a strategic growth initiative in a regulated environment.
CV Sciences, Inc. posted a revenue decline in Q3 2025, driven largely by lower sales volume. Despite this, the company remains focused on innovation and regulatory collaboration.
1933 Industries Inc. announced its financial results for the second quarter of fiscal 2026, noting revenue decline and resilience in its product offerings.